In patients with diabetes and coronary artery disease (CAD), reducing systolic blood pressure to less than 130 mm Hg does not lower cardiovascular events any more than standard control efforts. The findings were published in the July 7, 2010, issue of the Journal of the American Medical Association.

Rhonda M. Cooper-DeHoff, PharmD, MS, of the University of Florida (Gainesville, FL), and colleagues conducted an observational subgroup analysis of 6,400 diabetic participants in the International Verapamil SR-Trandolapril Study (INVEST), a prospective randomized trial that compared clinical outcomes of 22,576 patients with hypertension and CAD. Patients received first-line treatment with either a calcium ....

You must be a member to access this content. To continue reading, please enter your username and password above.

If you have not yet registered, we would like to take this opportunity to welcome you to TCTMD - The Source for Interventional Cardiovascular News & Education.

If you are already a member, please re-enter your username and password above, and then click LOGIN.

For questions regarding the registration process, please refer to our FAQ documentation or contact customer service.